Recombinant Flagellin A Proteins from *Borrelia burgdorferi* Sensu Stricto, *B. afzelii*, and *B. garinii* in Serodiagnosis of Lyme Borreliosis

JAANA PANELIUS,[1]* PEKKA LAHDENNE,[2] HARRI SAXEN,[2] TERO HEIKKILÄ,[1,2]
AND ILKKA SEPPÄLÄ[1,3]

*Haartman Institute, Department of Bacteriology and Immunology,[1] and Hospital for Children and
Adolescents,[2] University of Helsinki, and HUCH Laboratory Diagnostics,
Helsinki University Central Hospital,[3] Helsinki, Finland*

Genes for flagellin A (FlaA) proteins from European borrelial strains of *Borrelia burgdorferi* sensu stricto, *B. afzelii*, and *B. garinii* were cloned and sequenced. An identity of 92 to 93% was observed in the *flaA* sequences of the different species. Polyhistidine-tagged recombinant FlaA (rFlaA) proteins were produced in *Escherichia coli* and used as antigens in Western blotting (WB) and enzyme-linked immunosorbent assay (ELISA). In immunoglobulin G (IgG) WB, 71% (10 of 14) of the sera from neuroborreliosis and 86% (12 of 14) of those from Lyme arthritis patients reacted with one to three rFlaAs. In IgG ELISA, 74% (14 of 19) and 79% (15 of 19) of patients with neuroborreliosis and arthritis, respectively, were positive. The immunoreactivity in local European patient sera was stronger against rFlaA from *B. garinii* and *B. afzelii* than against rFlaA from *B. burgdorferi* sensu stricto. Neither IgG nor IgM ELISA was sensitive in the serodiagnosis of erythema migrans. Serum samples from patients with syphilis and systemic lupus erythematosus showed mild cross-reactivity in IgG tests. Sera from *Yersinia enterocolitica* or beta-hemolytic *Streptococcus* infections showed only occasional responses. With IgM ELISA, 58% (11 of 19) and 37% (7 of 19) of patients with neuroborreliosis and arthritis, respectively, were positive. Cross-reactive antibodies to FlaA, especially in serum samples from patients with rheumatoid factor positivity and Epstein-Barr virus infection, reduced the specificity of IgM serodiagnosis. Therefore, rFlaA seems to have a limited role for IgM serodiagnosis, yet rFlaA might be useful in the IgG serodiagnosis of disseminated Lyme borreliosis.

Laboratory diagnosis of Lyme borreliosis (LB) is mainly based on serology, although the present serologic tests have unsatisfactory sensitivity and specificity (34). Routine laboratory testing uses enzyme-linked immunosorbent assays (ELISA) with borrelial whole-cell lysate (WCL) or flagella (consisting mainly of polymerized FlaB protein) as the most commonly used antigens. A two-step approach with ELISA followed by a confirmatory Western blot (WB) has been recommended for positive or borderline results (19, 36). Especially in Europe, the applicability of this procedure has, however, remained doubtful (3, 14) because three or more borrelial species cause LB (38). Several difficulties complicate LB serology. Firstly, immunoglobulin G (IgG) antibody responses are often delayed during the early stages of LB. Even at late-stage LB, 5 to 10% of patients do not have elevated antibody levels (29), perhaps due to diversion of the host immune response towards Th1 immunity by borrelial factors (17). Secondly, viral infections cause false-positive IgM results in several LB tests (4). Thirdly, in a subgroup of patients antibody levels may stay high after successful treatment of LB even for prolonged periods (6, 15).

Several recombinant borrelial antigens (OspA, OspB, OspC, OspE, OspF, p22, BmpA, BBK32, BBK50, VlsE, p100, 14-kDa internal flagellin fragment) (5, 7, 16, 21, 22, 24, 25, 31, 35) and chimeric borrelial proteins OspA, OspB, OspC, flagellin (p41), and p93 (13) have been studied to improve serologic diagnosis. Of these proteins, BmpA (32) and OspC (8, 26, 27, 30, 31) have been suggested as antigens which induce early IgM responses. However, IgG antibodies to recombinant BmpA have been detected mainly in long-standing disease (29, 32). A limiting factor in the use of OspC as a diagnostic antigen is the extensive structural variation of the molecule between borrelial species (18, 23). Use of recombinant antigens has increased the specificity of serologic assays, but the sensitivity of tests using single antigens has thus far remained disappointing. In Europe, where the sequence heterogeneity of antigenic proteins in various borrelial species and strains complicates LB serology (33), supplementary information is needed on the differences between the antigenic properties of the borrelial species.

Flagellin A (FlaA) is a 37-kDa outer sheath protein of the periplasmic *Borrelia burgdorferi* flagella. It has been suggested that FlaA could potentially be a useful antigen for detecting antibodies in early LB. Gilmore et al. (12) obtained promising results for erythema migrans (EM) patients with IgM WB using recombinant FlaA (rFlaA) as an antigen. In contrast, Ge et al. (9) failed to show any useful serologic role in LB for another rFlaA construct. The purpose of the present study was to expand our knowledge of FlaA proteins in *B. burgdorferi* sensu lato spirochetes. We present the cloning and expression of FlaA proteins from three European borrelial strains of *B. burgdorferi* sensu stricto, *B. afzelii*, and *B. garinii* and the results

---

* Corresponding author. Mailing address: Haartman Institute, Department of Bacteriology and Immunology, P.O. Box 21, University of Helsinki, Helsinki, FIN-00014, Finland. Phone: (358)-9-1911. Fax: (358)-9-19126382. E-mail: jaana.panelius@helsinki.fi.

TABLE 1. Primers used in PCR reactions for *flaA* sequencing and expression of the respective protein

Target DNA	Primer (5′-3′)[a]	Location (bp)
Sequencing		
1	ATA TAA GGA GTT GGT TTA CAT	−19–2
2	ATG AAA AGG AAA GCT AAA AGT	1–21
3	GCT ATT CTC AAT CAT CTG C	386–404
4	TTT ATG AGA CTA GCG GAA CT	860–879
5	TTA AAT AAA CCT TGC CAT CAA	1,438–1,418
6	TTT TCT AAA TCT AAT ATT TCC AT	1,117–1,094
7	CAT TTT ACT TGA AGC AAG AG	717–698
Expression		
FlaA$_{Bbia}$	CCG GAT CCG ATG GAT TAG CAG AGG GTT	67–85
	CCG GTA CCC TAA TTT TTC GGA GAT GAT TC	1,026–1,006
FlaA$_{BaA91}$	CCG GAT CCG ATG GAT TAA CAG AGG GC	67–84
	CCG GTA CCC TAA TTT TCT GAA GAT GAT TC	1,026–1,006
FlaA$_{Bg46}$	CCG GAT CCG ATG GAT TGC CAG AAG GC	67–84
	CCG GTA CCC TAC TTT TTT AAG GAT GAT TC	1,029–1,009

[a] Underlining indicates *Bam*HI and *Kpn*I cleavage sites.

of WB assays and ELISAs using FlaA recombinants as antigens.

MATERIALS AND METHODS

Borrelial strains. Domestic borrelial strains of *B. burgdorferi* sensu stricto (ia) isolated from cerebrospinal fluid and *B. afzelii* (A91) and *B. garinii* (46) isolated from skin biopsies of Finnish patients with LB were used. The genotyping of these strains was performed by PCR of *flaB* and subsequent sequencing of the PCR products, as described previously (20).

Borrelia culture and DNA isolation. Borrelial strains were cultured in Barbour-Stoenner-Kelly-H medium (Sigma) at 33°C and in a 5% CO_2 atmosphere until the growth was approximately 2×10^8 cells/ml. The genomic DNA was isolated with a DNeasy Tissue kit (Qiagen, Hilden, Germany).

PCR and cloning of the genes. For each borrelial strain the *flaA* sequence was studied by PCR amplification of the genomic DNA (Table 1). Approximately 1 ng of template DNA was used and the parameters in the PCR amplification reaction were 30 cycles at 94°C for 1 min, 50°C for 1 min, and 72°C for 1 min 30 s with AmpliTaq Gold DNA polymerase (Perkin Elmer). DNA products were

visualized by gel electrophoresis on a 1% Agarose NA gel (Amersham Pharmacia, Uppsala, Sweden) containing ethidium bromide. The PCR products were cloned into the pCR 2.1-TOPO vector (Invitrogen, Groningen, The Netherlands). *Escherichia coli* INFαF (Invitrogen) host cells were used for cloning.

DNA sequencing. Plasmid DNA containing *flaA* inserts was isolated from *E. coli* by using a QIAprep-Spin plasmid kit (Qiagen). DNA sequencing was performed with the DyePrimer (T7, M13Rev) cycle sequencing kit (Applied Biosystems Inc.) in accordance with the manufacturer's instructions by the Core Facility of the Haartman Institute, University of Helsinki. Sequencing reactions were run and analyzed by an automated sequencing apparatus model 373A (Applied Biosystems, Inc.). DNA and protein sequences were analyzed with Lasergene software (DNASTAR, Inc.). To eliminate possible sequencing errors, the whole gene was sequenced twice, and in some cases three times, following discordant results.

Construction of the expression plasmid and expression of rFlaA. The starting codon for the *flaA* construct was chosen according to previous successful experiences of other investigators to express FlaA (12). The *flaA* constructs included the protein coding sequence without the sequence for the leader and three subsequent codons encoding the first three amino acids after a predicted signal

FIG. 1. FlaA amino acid sequence comparison of the translated full-length gene in *B. burgdorferi* sensu stricto strains B31, 212, and ia (Bbia), *B. afzelii* A91 (BaA91), and *B. garinii* 46 (Bg46). Boxes indicate amino acid heterogeneity. The starting point of our recombinant constructs is indicated by an arrow.

peptidase I cleavage site (28) (Fig. 1). Expression primers for *flaA* of each strain were designed individually (Table 1), and the gene area to be expressed was multiplied by PCR and inserted into the pCR 2.1-TOPO vector as above. The plasmid containing the insert was purified and digested with *Bam*HI and *Kpn*I. The cleaved *flaA* was ligated into similarly cut pQE-30 expression plasmid (Qiagen) with T4 ligase. The ligation mixture was used to transform *E. coli* M15 host cells as described in the manufacturer's instructions (Qiagen). The transformation mixture was plated onto Luria-Bertani agar containing 100 μg of ampicillin and 25 μg of kanamycin per ml. A primary culture for expression of rFlaA was started by inoculating a single colony from a fresh transformant plate into 50 ml of Luria-Bertani broth containing antibiotics as described above. The culture was incubated at 37°C with shaking overnight. This starter culture was diluted 1:100 to 1,500 ml of Luria-Bertani broth with antibiotics as described above and incubated at 37°C for 3 h (the growth reached the mid-log phase; the optical density at 600 nm was ca. 0.6). Isopropyl-β-D-thiogalactoside (Calbiochem) was added to a final concentration of 0.6 mM, and an additional incubation of 3 h was performed. The cells were harvested, washed, and sonicated. The expressed rFlaA was recovered as insoluble protein in the centrifugation pellet. This was dissolved in 4 M guanidine hydrochloride and attached by its 6xHistidine tag to a Chelating Sepharose Fast Flow column (Amersham Pharmacia) containing Ni^{2+}. rFlaA was subsequently eluted from the column by 160 mM imidazole–4 M guanidine hydrochloride eluting buffer. Protein expression and purity were confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

Purification of rFlaA. rFlaAs originating from *B. burgdorferi* sensu stricto ia, *B. afzelii* A91, and *B. garinii* 46 (referred to as rFlaA$_{Bbia}$, rFlaA$_{BaA91}$, and rFlaA$_{Bg46}$, respectively) were dialyzed in 10 mM potassium phosphate (pH 7.2). After centrifugation the resulting insoluble protein pellet was resolubilized in 4 M guanidine hydrochloride when used for WB or in 5 M urea when used for ELISA.

The insolubility of the rFlaA protein complicated reliable measurement of the protein concentration by either spectrophotometry or chemical assay methods. For WB and ELISA, protein concentrations of rFlaA preparations were estimated by comparing the intensity of FlaA bands with known concentrations of bovine serum albumin (BSA) in SDS-PAGE after Coomassie blue staining or Ponceau S staining after transfer to nitrocellulose.

WB. rFlaA was applied to SDS-PAGE gels (12.5% gels) and transferred to a nitrocellulose membrane (Bio-Rad) by semidry transfer with 40 mM glycine–50 mM Tris (pH 9.0)–0.375% (wt/vol) SDS–20% (vol/vol) methanol buffer. For IgM WB, serum samples were incubated at a dilution of 1:500 in BSA (5 mg/ml) in 155 mM NaCl–0.04% Tween 20 buffer (BSA-NaCl-Tween) for 2 h. For IgG WB, a serum dilution of 1:75 in 0.1% Tween 20–0.9% NaCl was used. After washing, the blots were incubated with alkaline phosphatase-conjugated rabbit anti-human IgM or IgG (Jackson Immuno Research Laboratories Inc.) for 2 h. In control experiments the anti-IgM conjugate showed a faint FlaA band in the absence of serum. Therefore, the conjugate was absorbed with rFlaA from *B. afzelii*. FlaA in coupling buffer (0.6 M NaCl–125 mM NaHCO$_3$) was added to tresyl-activated Sepharose 4B (Amersham Pharmacia) beads. After incubation for 16 h and centrifugation the beads were washed with the coupling buffer, and the conditions were alternated three times between 0.1 M Tris buffer (pH 8.0)–0.5 M NaCl and 0.1 M acetate buffer (pH 4.0)–0.5 M NaCl. The IgM conjugate was added to the beads and centrifuged after 2 h of incubation. The supernatant was used at a 1:8,000 final dilution for the IgM WB. The IgG conjugate was used without FlaA immunoabsorption at a 1:5,000 dilution. After washing, the visualization was done with 5-bromo-4-chloro-3-indolylphosphate-Nitro Blue Tetrazolium (Sigma). The intensity of WB bands was evaluated visually and with MacBAS 2.5 software (Koshin Graphic Systems, Inc.). In the MacBAS program the mean of the intensity values of blood donor samples was calculated. Values above the mean plus 2 standard deviations (SD) were defined as positive.

ELISA. For rFlaA ELISA, microtiter plate wells were coated with 200 ng of rFlaA in 5 M urea overnight at +4°C. With intervening washes the sera and reagents were sequentially incubated in the wells as follows: serum samples at a dilution of 1:100 in BSA-NaCl-Tween overnight at +4°C, alkaline phosphatase-conjugated rabbit anti-human IgM or IgG (Jackson Immuno Research Laboratories Inc.) at a dilution of 1:5,000 in BSA-NaCl-Tween for 2 h, and 4-nitrophenylphosphate (Boehringer Mannheim, Mannheim, Germany) substrate in diethanolamine buffer (pH 10.0) for 15 min. The absorbance at 405 nm was measured by using a Multiscan photometer (Thermo Labsystems, Helsinki, Finland).

Patients. Human serum samples were collected from patients with typical LB (primary EM, neuroborreliosis [NB], or Lyme arthritis [LA]). For all patients, the diagnosis of LB was based on clinical guidelines for diagnosis set forth by the Centers for Disease Control and Prevention, Atlanta, Ga. (39). The clinical diagnosis of NB and LA was confirmed by demonstrating antibodies in serum by ELISA against WCL from *B. afzelii* strain SK1 and flagella from *B. afzelii* DK1 (Dako, Ely, United Kingdom), and for patients with NB, the diagnosis was confirmed by demonstrating antibodies to flagella in cerebrospinal fluid. For all patients with EM, the diagnosis was confirmed by culturing *B. burgdorferi* from a skin biopsy (11 *B. afzelii* and 4 *B. garinii*). Serum samples were obtained from patients with syphilis, rheumatoid factor (RF) positivity, antistreptolysin (ASO) positivity, Epstein-Barr virus (EBV) infection, high *Yersinia enterocolitica* antibody titers with positive stool culture, and clinically and serologically verified systemic lupus erythematosus (SLE), and samples from healthy blood donors were used as controls.

Nucleotide sequence accession numbers. *flaA* sequences from *B. burgdorferi* strain ia, *B. afzelii* A91, and *B. garinii* 46 have been assigned to the GenBank database with accession numbers AY057222, AY057223, and AY057224, respectively. Published *flaA* sequences from *B. burgdorferi* sensu stricto strains B31 and 212 were obtained from GenBank (accession no. AE001168 and U62900, respectively).

RESULTS

Cloning and nucleotide sequence analysis of *flaA*. *flaA* nucleotide sequences of the borrelial strains were obtained by PCR and sequencing. The primers were designed according to the published flanking region sequences to ensure correct sequences at the gene ends. The analyzed sequences were compared with the published *flaA* sequences of *B. burgdorferi* sensu stricto strains B31 and 212. The *flaA* sequence of the *B. burgdorferi* sensu stricto strain ia was identical with that of the American strain B31 whereas it differed by nine nucleotides (identity of 99% at the nucleotide level) from the *flaA* sequence in strain 212. The identity of *flaA* sequences between the Finnish strains *B. burgdorferi* sensu stricto ia and *B. afzelii* A91, between *B. burgdorferi* sensu stricto ia and *B. garinii* 46, and between *B. afzelii* A91 and *B. garinii* 46 was 93, 92, and 93%, respectively. The identity of *flaA* in *B. afzelii* A91 and in *B. garinii* 46 compared to *flaA* in strain 212 was 92 and 91%, respectively.

Protein sequence analysis. The deduced amino acid sequences of FlaA$_{Bbia}$, FlaA$_{BaA91}$, and FlaA$_{Bg46}$ were 95% identical (Fig. 1). The identity of both FlaA$_{BaA91}$ and FlaA$_{Bg46}$ with FlaA of *B. burgdorferi* sensu stricto 212 was 94%. The *flaA* gene of *B. garinii* 46 has an additional triplet of nucleotides, AAA, at positions 1000 to 1002, leading to a lysine insertion into an otherwise hydrophilic sequence area. None of the sequence differences change the local hydrophilicity of the sequence area, indicating conservation of the overall structure (Fig. 1). The deduced amino acid sequence of FlaA protein (without the leader peptide) was rich in phenylalanine and tyrosine (15 and 16 amino acids, respectively) but contained no cysteine. The count of these amino acids was identical in all three FlaA proteins examined in this study. Thirty-three percent of the deduced amino acids were hydrophobic. The calculated (Lasergene Software; DNASTAR, Inc.) isoelectric points of FlaA$_{Bbia}$, FlaA$_{BaA91}$, and FlaA$_{Bg46}$ for the mature protein without leader sequence were 5.70, 5.33, and 7.27, respectively. Three additional lysines and fewer aspartic acids in FlaA$_{Bg46}$ than in FlaA$_{Bbia}$ and FlaA$_{BaA91}$ may account for the higher isoelectric point of FlaA$_{Bg46}$.

IgG WB. For the WB analysis, serum samples from 14 patients with NB, 14 with LA, 10 with syphilis, and 13 healthy blood donors were tested. Ten samples from patients with NB (71%) and 12 from patients with LA (86%) reacted with one or

TABLE 2. IgG WB results with rFlaA antigen from *B. garinii*, *B. afzelii*, and *B. burgdorferi* sensu stricto

Antigen	No. of patients with a positive result for the indicated antigen			
	NB patients ($n = 14$)	LA patients ($n = 14$)	Syphilis patients ($n = 10$)	Healthy blood donors ($n = 13$)
rFlaA$_{Bg46}$	9	12	0	1
rFlaA$_{BaA91}$	9	6	0	0
rFlaA$_{Bbia}$	6	5	2	0
Total[a]	10	12	2	1

[a] Total refers to the total number of patients in each group having antibodies to one or more of the rFlaA proteins.

more of the rFlaAs. Two of 10 patients with syphilis and 1 out of 13 healthy blood donors were positive. The combined results of the WB analysis are presented in Table 2. rFlaA$_{Bg46}$ and rFlaA$_{BaA91}$ were superior to rFlaA$_{Bbia}$ in detecting antibodies to FlaA.

IgM WB. In repeated experiments using serum samples from patients with EM or NB, we consistently observed moderate to strong IgM immunoreactivity to rFlaAs, yet samples from patients with EBV infection or RF positivity were similarly immunoreactive. However, the evaluation of the immunoblot bands visually and with the MacBAS program showed differences in the intensity of the bands (data not shown). Based on the intensities of healthy blood donor serum reactions, one of five samples from patients with EM, four of five from patients with NB, two of five from patients with EBV, and two of five with RF positivity gave positive IgM reactions for one or more of the rFlaAs. Alterations in the dilution of the serum (1:25 to 1:500), the buffer (varying the protein and using different salt concentrations), or the applied conjugate did not lead to any better discrimination of the IgM bands between the patients and the controls (data not shown).

IgG ELISA. For IgG ELISA optical density values above the means plus 2 SD of values of healthy blood donors were defined as positive. Results for IgG ELISA of LB patients were comparable with the results obtained from IgG WB analysis: positive reactions were found mainly against rFlaA$_{Bg46}$ and rFlaA$_{BaA91}$ while reactions to rFlaA$_{Bbia}$ were less frequent (Fig. 2). Of the samples from 15 patients with EM, two (13%) of the acute-phase samples and three (20%) of the convalescent-phase samples reacted with one or more of the rFlaAs. Samples from 14 of the 19 (74%) patients with NB and from 15 of 19 (79%) patients with LA reacted with either rFlaA$_{Bg46}$ or rFlaA$_{BaA91}$. The 19 patient samples of NB and LA used here include those examined by IgG WB. None of the samples from patients with NB or LA reacted with rFlaA$_{Bbia}$ only. Twelve of the 14 positive samples from NB patients recognized both rFlaA$_{BaA91}$ and rFlaA$_{Bg46}$, and the remaining 2 recognized rFlaA$_{Bg46}$ only. Of the 15 positive samples from LA patients, 11 recognized both antigens, 2 recognized rFlaA$_{BaA91}$ only, and 2 recognized rFlaA$_{Bg46}$ only. Depending on the rFlaA antigen used, 1 to 3 of 10 patients with syphilis, 1 to 2 of 8 patients with RF positivity, 0 to 3 of 8 patients with ASO positivity, 1 to 3 of 8 patients with EBV infection, 0 to 2 of 8 patients with *Yersinia* infection, 2 to 3 of 8 patients with SLE, and 2 of 27 healthy blood donors were positive.

IgM ELISA. IgM ELISA was performed with the same panel of patient and control samples as the IgG ELISA. Of the 15 samples from patients with EM, 3 (20%) of the acute-phase samples and 4 (27%) of the convalescent-phase samples reacted with one or more of the rFlaAs. Samples from 11 of the 19 (58%) patients with NB and from 7 of 19 (37%) patients with LA reacted with one or more of the rFlaAs. Depending on the rFlaA antigen used, 0 to 1 of 10 patients with syphilis, 2 to 4 of 8 patients with RF positivity, 1 to 8 of 8 patients with ASO positivity, 2 to 6 of 8 patients with EBV infection, 1 to 4 of 8 patients with *Yersinia* infection, 1 of 8 patients with SLE, and 1 of 27 healthy blood donors were positive. Results with three variant rFlaAs as antigen in the IgM ELISA are shown in Fig. 2.

DISCUSSION

In the present study, *flaA* sequences of *B. afzelii* and *B. garinii* are reported for the first time. The identity of the *flaA* sequences of *B. afzelii*, *B. garinii*, and *B. burgdorferi* sensu stricto was over 90%. Although the exact function of the FlaA protein is not known, it has been shown that periplasmic flagellae of *B. burgdorferi* comprise a core protein FlaB and an outer sheath protein FlaA (11). Given the essential role of flagella in motility of the spirochete it is not surprising that the *flaA* was highly conserved among *B. burgdorferi* sensu lato strains.

FlaA has been evaluated as a WB antigen in LB serodiagnosis in only a few studies, and the results have been contradictory (9, 12). No previous studies using rFlaA in ELISA have been published. Our aim was to study the antigenic potential of FlaA in the European context. Therefore, we cloned *flaA* from all three borrelial species and produced the respective recombinant proteins. For IgG serodiagnosis of NB and LA, FlaA appeared to be a sensitive antigen. Seventy-one or seventy-four percent of patients with NB were positive either by WB or ELISA, respectively. The corresponding positivities for LA patient samples were 86 and 79%. The specificity in our series was slightly lowered due to low positive values occurring more frequently in samples from other diseases than in samples from healthy controls. Although the sequences of the three FlaA proteins were highly homologous, rFlaA antigens from *B. garinii* and *B. afzelii* seemed to perform better regarding sensitivity and specificity than rFlaA from *B. burgdorferi* sensu stricto. Obviously, various FlaA proteins have both common and divergent antigenic epitopes. In Europe, *B. garinii* and *B. afzelii* are the most prevalent genospecies (38). This concurs with the predominance of immunoreactivity to rFlaA from these two genospecies.

In IgM serology our patient selection differed from the series by Gilmore et al. (12). They studied EM patient sera with antibodies to the *B. burgdorferi* 37-kDa protein (putative FlaA antigen) in WCL immunoblot which also reacted with the rFlaA. However, only 38 and 57% of all patients with EM at the acute and convalescent phase, respectively, had antibodies to rFlaA (12). Serum samples from EM patients with no observed immunoreactivity against the *B. burgdorferi* 37-kDa protein did not recognize rFlaA (12). It is not clear how the group of EM patients without immunoreactivity to rFlaA differed from those reacting positively with rFlaA. In our study with unselected culture-confirmed EM patients, sensitivity of the

IgG　　　　　　　　　　　　　　　　　　　　IgM

FIG. 2. IgG and IgM ELISA results with rFlaA proteins from *B. garinii* (Bg46) (A), *B. afzelii* (BaA91) (B), and *B. burgdorferi* sensu stricto (Bbia) (C) as antigens. Optical density (OD) values for each patient group and control samples are shown separately. Serum samples were from patients with EM at the acute phase (EM1), EM at the convalescent phase (EM2), NB, LA, syphilis (SY), RF positivity (RF+), ASO positivity, EBV infection, *Yersinia* infection (YE), and SLE and from healthy blood donors (BD). The cutoff level (mean + 2 SD of blood donor samples) for each antigen is indicated by a line.

IgM serology in WB and ELISA assays was only 20 to 27%. Another study failed to show FlaA as an immunodominant antigen in LB (9). The authors did not specify whether an IgM or IgG WB or early- or convalescent-phase serum samples of LB patients were used. In our assays for EM patient samples, IgG ELISA performed almost equally with IgM ELISA. For NB patients, IgG FlaA ELISA had better sensitivity than IgM ELISA. It is possible that our patient selection, including NB patients at early and late stages, may account for this finding. Furthermore, cross-reactive antibodies to FlaA reduced the specificity of IgM serodiagnosis both in WB and ELISA experiments. Possibly, antibodies to FlaA of ubiquitous bacteria account for the cross-reactivity in IgM serology. Therefore, we do not see rFlaA as a useful antigen in IgM serodiagnosis for early LB.

As is typical for signal sequences, the leader of the FlaA protein includes a central hydrophobic segment (10). Trials to express a construct with the N-terminal leader have failed (12), perhaps due to toxicity to the *E. coli* host cell. However, as shown by Gilmore et al. (12) and in our study, FlaA without the leader peptide was well expressed, yet our recombinant protein tended to form inclusion bodies. The Protein Analysis program (Lasergene) predicted a β-sheet-rich region between amino acids 50 and 180 of the full-length protein (data not shown). We anticipate that this region of FlaA is involved in binding to the FlaB protein in the flagellar structure and may contribute to its property to form inclusions. A more hydrophilic construct formed by exclusion of the N-terminal part of FlaA might lead to a soluble recombinant protein. However, in another laboratory a construct where the first 79 amino acids were excluded failed to lead to successful expression (12).

Unlike in other spirochetes, *B. burgdorferi* FlaA is expressed at a considerably lower level than FlaB (11). The surface of borrelial flagella may have only a small amount of FlaA protein

attached to the FlaB backbone, leaving a large part of the FlaB surface uncovered. This is in accordance with the observed difficulty of demonstrating flagellar sheaths in *Borrelia* (2). The smaller amount of FlaA protein expressed by *Borrelia* spp. during infection than of FlaB may account for the difficulty in finding specific IgM or IgG to FlaA and to the lower proportion of patients with positive immunoreactivity to FlaA than to FlaB. Alternatively, differences in the time of collection of sera with respect to clinical course might cause discrepancies in the immunoreactivity.

Besides *Borrelia* immunity, FlaA in other bacteria may be associated with interesting phenomena. In another spirochete disease, syphilis, the endoflagellar sheath protein of *Treponema pallidum*, TpN37, which is the product of *flaA*, has been shown to elicit a strong T-cell response (1). A recent study reported an amino acid sequence in FlaA of *Campylobacter jejuni* for which an association with Guillain-Barré syndrome was proposed (37).

In conclusion, FlaA seemed to be a sensitive antigen in the IgG serodiagnosis of disseminated LB. In IgM serology, low sensitivity in early LB and poor specificity may constrain its use to routine serodiagnosis. Regardless of the high homology of FlaA proteins within *Borrelia* genospecies, the present results suggest that recombinant proteins from *B. garinii* and/or *B. afzelii* should be preferred when rFlaA is used in the IgG serodiagnosis of LB in Europe.

REFERENCES

1. **Arroll, T. W, A. Centurion-Lara, S. A. Lukehart, and W. C. van Voorhis.** 1999. T-cell responses to *Treponema pallidum* subsp. *pallidum* antigens during the course of experimental syphilis infection. Infect. Immun. **67:**4757–4763.
2. **Barbour, A. G., and S. F. Hayes.** 1986. Biology of *Borrelia* species. Microbiol. Rev. **50:**381–400.
3. **Blaauw, A. A. M., A. M. van Loon, J. F. P. Schellekens, and J. W. J. Bijlsma.** 1999. Clinical evaluation of guidelines and two-test approach for Lyme disease. Rheumatology **38:**1121–1126.
4. **Brown, S. L., S. L. Hansen, and J. J. Langone.** 1999. Role of serology in the diagnosis of Lyme disease. JAMA **282:**62–66.
5. **Buckert, S., D. Rössler, P. Munchhoff, and B. Wilske.** 1996. Development of enzyme-linked immunosorbent assays using recombinant borrelial antigens for serodiagnosis of *Borrelia burgdorferi* infection. Med. Microbiol. Immunol. **185:**49–57.
6. **Craft, J. E., R. L. Grodzicki, and A. C. Steere.** 1984. Antibody response in Lyme disease: evaluation of diagnostic tests. J. Infect. Dis. **149:**789–795.
7. **Fikrig, E., S. W. Barthold, W. Sun, W. Feng, S. R. Telford, and R. A. Flavell.** 1997. *Borrelia burgdorferi* P35 and P37 proteins, expressed in vivo, elicit protective immunity. Immunity **6:**531–539.
8. **Fung, B. P., G. L. McHugh, J. M. Leong, and A. C. Steere.** 1994. Humoral immune response to outer surface protein C of *Borrelia burgdorferi* in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection. Infect. Immun. **62:**3213–3221.
9. **Ge, Y., and N. W. Charon.** 1997. FlaA, a putative flagellar outer sheath protein, is not an immunodominant antigen associated with Lyme disease. Infect. Immun. **65:**2992–2995.
10. **Ge, Y., and N. W. Charon.** 1997. An unexpected *flaA* homolog is present and expressed in *Borrelia burgdorferi*. J. Bacteriol. **179:**552–556.
11. **Ge, Y., C. Li, L. Corum, C. A. Slaughter, and N. W. Charon.** 1998. Structure and expression of the FlaA periplasmic flagellar protein of *Borrelia burgdorferi*. J. Bacteriol. **180:**2418–2425.
12. **Gilmore, R. D., Jr., R. L. Murphree, A. M. James, S. A. Sullivan, and B. J. B. Johnson.** 1999. The *Borrelia burgdorferi* 37-kilodalton immunoblot band (P37) used in serodiagnosis of early Lyme disease is the *flaA* gene product. J. Clin. Microbiol. **37:**548–552.
13. **Gomes-Solecki, M. J. C., J. J. Dunn, B. J. Luft, J. Castillo, D. E. Dykhuizen, X. Yang, J. D. Glass, and R. J. Dattwyler.** 2000. Recombinant chimeric *Borrelia* proteins for diagnosis of Lyme disease. J. Clin. Microbiol. **38:**2530–2535.
14. **Goossens, H. A. T., A. E. van den Bogaard, and M. K. E. Nohlmans.** 1999. Evaluation of fifteen commercially available serological tests for diagnosis of Lyme borreliosis. Eur. J. Clin. Microbiol. Infect. Dis. **18:**551–560.
15. **Hammers-Berggren, S., A.-M. Lebech, M. Karlsson, U. Andersson, K. Hansen, and G. Stiernstedt.** 1994. Serological follow-up after treatment of *Borrelia* arthritis and acrodermatitis chronica atrophicans. Scand. J. Infect. Dis. **26:**339–347.
16. **Hauser, U., G. Lehnert, and B. Wilske.** 1998. Diagnostic value of proteins of three *Borrelia* species (*Borrelia burgdorferi* sensu lato) and implications for development and use of recombinant antigens for serodiagnosis of Lyme borreliosis in Europe. Clin. Diagn. Lab. Immunol. **5:**456–462.
17. **Infante-Duarte, C., H. F. Horton, M. C. Byrne, and T. Kamradt.** 2000. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. **165:**6107–6115.
18. **Jauris-Heipke, S., G. Liegl, V. Preac-Mursic, D. Rössler, E. Schwab, E. Soutschek, G. Will, and B. Wilske.** 1995. Molecular analysis of genes encoding outer surface protein C (OspC) of *Borrelia burgdorferi* sensu lato: relationship to *ospA* genotype and evidence of lateral gene exchange of *ospC*. J. Clin. Microbiol. **33:**1860–1866.
19. **Johnsson, B. J. B., K. E. Robbins, R. E. Bailey, B.-L. Cao, S. L. Sviat, R. B. Craven, L. W. Mayer, and D. T. Dennis.** 1996. Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting. J. Infect. Dis. **174:**346–353.
20. **Junttila, J., M. Peltomaa, H. Soini, M. Marjamäki, and M. K. Viljanen.** 1999. Prevalence of *Borrelia burgdorferi* in *Ixodes ricinus* ticks in urban recreational areas of Helsinki. J. Clin. Microbiol. **37:**1361–1365.
21. **Lawrenz, M. B., J. M. Hardham, R. T. Owens, J. Nowakowski, A. C. Steere, G. P. Wormser, and S. J. Norris.** 1999. Human antibody responses to VlsE antigenic variation protein of *Borrelia burgdorferi*. J. Clin. Microbiol. **37:**3997–4004.
22. **Liang, F. T., A. C. Steere, A. R. Marques, B. J. B. Johnson, J. N. Miller, and M. T. Philipp.** 1999. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of *Borrelia burgdorferi* VlsE. J. Clin. Microbiol. **37:**3990–3996.
23. **Livey, I., C. P. Gibbs, R. Schuster, and F. Dorner.** 1995. Evidence for lateral transfer and recombination in OspC variation in Lyme disease Borrelia. Mol. Microbiol. **18:**257–269.
24. **Magnarelli, L. A., E. Fikrig, S. J. Padula, J. F. Anderson, and R. A. Flavell.** 1996. Use of recombinant antigens of *Borrelia burgdorferi* in serologic tests for diagnosis of Lyme borreliosis. J. Clin. Microbiol. **34:**237–240.
25. **Magnarelli, L. A., J. W. Ijdo, S. J. Padula, R. A. Flavell, and E. Fikrig.** 2000. Serologic diagnosis of Lyme borreliosis by using enzyme-linked immunosorbent assays with recombinant antigens. J. Clin. Microbiol. **38:**1735–1739.
26. **Mathiesen, M. J., A. Holm, M. Christiansen, J. Blom, K. Hansen, S. Ostergaard, and M. Theisen.** 1998. The dominant epitope of *Borrelia garinii* outer surface protein C recognized by sera from patients with neuroborreliosis has a surface-exposed conserved structural motif. Infect. Immun. **66:**4073–4079.
27. **Mathiesen, M. J., M. Christiansen, K. Hansen, A. Holm, E. Åsbrink, and M. Theisen.** 1998. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. J. Clin. Microbiol. **36:**3474–3479.
28. **Nielsen, H., J. Engelbrecht, S. Brunak, and G. von Heijne.** 1997. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng. **10:**1–6.
29. **Oksi, J., J. Uksila, M. Marjamäki, J. Nikoskelainen, and M. K. Viljanen.** 1995. Antibodies against whole sonicated *Borrelia burgdorferi* spirochetes, 41-kilodalton flagellin, and P39 protein in patients with PCR- or culture-proven late Lyme borreliosis. J. Clin. Microbiol. **33:**2260–2264.
30. **Padula, S. J., F. Dias, A. Sampieri, R. B. Craven, and R. W. Ryan.** 1994. Use of recombinant OspC from *Borrelia burgdorferi* for serodiagnosis of early Lyme disease. J. Clin. Microbiol. **32:**1733–1738.
31. **Rauer, S., N. Spohn, C. Rasiah, U. Neubert, and A. Vogt.** 1998. Enzyme-linked immunosorbent assay using recombinant OspC and the internal 14-kDa flagellin fragment for serodiagnosis of early Lyme disease. J. Clin. Microbiol. **36:**857–861.
32. **Roessler, D., U. Hauser, and B. Wilske.** 1997. Heterogeneity of BmpA (P39) among European isolates of *Borrelia burgdorferi* sensu lato and influence of interspecies variability on serodiagnosis. J. Clin. Microbiol. **35:**2752–2758.
33. **Ryffel, K., O. Peter, B. Rutti, A. Suard, and E. Dayer.** 1999. Scored antibody reactivity determined by immunoblotting shows an association between clinical manifestations and presence of *Borrelia burgdorferi* sensu stricto, *B. garinii*, *B. afzelii*, and *b. valaisiana* in humans. J. Clin. Microbiol. **37:**4086–4092.
34. **Sigal, L. H.** 1998. Pitfalls in the diagnosis and management of Lyme disease. Arthritis Rheum. **41:**195–204.
35. **Theisen, M., B. Frederiksen, A.-M. Lebech, J. Vuust, and K. Hansen.** 1993.

Polymorphism in *ospC* gene of *Borrelia burgdorferi* and immunoreactivity of OspC protein: implications for taxonomy and for use of OspC protein as a diagnostic antigen. J. Clin. Microbiol. **31:**2570–2576.
36. **Trevejo, R. T., P. J. Krause, V. K. Sikand, M. E. Schriefer, R. Ryan, T. Lepore, W. Porter, and D. T. Dennis.** 1999. Evaluation of two-test serodiagnostic method for early Lyme disease in clinical practice. J. Infect. Dis. **179:**931–938.
37. **Tsang, R. S. W., G. Figueroa, L. Bryden, and L.-K. Ng.** 2001. Flagella as a potential marker for *Campylobacter jejuni* strains associated with Guillain-Barré syndrome. J. Clin. Microbiol. **39:**762–764.
38. **Wang, G., A. P. van Dam, I. Schwartz, and J. Dankert.** 1999. Molecular typing of *Borrelia burgdorferi* sensu lato: taxonomic, epidemiological, and clinical implications. Clin. Microbiol. Rev. **12:**633–653.
39. **Wharton, M., T. L. Chorba, R. L. Vogt, D. L. Morse, and J. W. Buehler.** 1990. Case definitions for public health surveillance. Morb. Mortal. Wkly. Rep. **39:**19–21.